Langhua Pharmaceuticals Snares $80M in Series A

According to VCBeat, on July 13, 2020, Langhua Pharmaceuticals, a Chinese company focused on the field of rare diseases, announced the completion of an US$80 million Series A financing, led by Quan Capital, an investment institution in medical and healthcare industry. Other investors include 3H Health Investment and Wu Capital. Existing investors Eight Roads, F-Prime Capital and Vivo Capital also made additional investments. 

As a treatment platform for rare diseases, Langhua Pharmaceuticals is committed to introducing rare disease drugs to the Chinese market and establishing the first ecosystem of rare disease treatment in China to help tens of millions of Chinese patients with rare diseases in urgent need of help.

Since its establishment in 2019, Langhua Pharmaceuticals has assembled a first-class senior management team. The team members have decades of work experience in rare diseases and the Chinese medical and healthcare industry.

Langhua Medical uses Internet tools and big data analysis technology to establish a platform to provide services for the entire rare disease community, aiming to raise public awareness of rare diseases, provide support for doctors and patients in testing and diagnosis and assist in the overall disease management.

Lin Rui, a partner of Eight Roads and a member of the board of Langhua Pharmaceuticals, said, "Langhua is committed to introducing safe and effective medicines for patients with rare diseases in China. Our goal is to establish a patient-centric ecosystem for rare diseases. By working hand-in-hand with various stakeholders, the problem of accessibility and affordability of medicines will be fundamentally resolved."

In recent years, Chinese authorities have issued a number of policies to encourage the introduction, R&D and production of rare disease drugs, and speed up the registration and approval of them. Now, clinical trial data obtained overseas for specific rare disease drugs can be directly submitted in China for approval. Langhua Pharmaceuticals will focus on proven drugs while speeding up the development of drugs worldwide.

Quan Capital is a venture firm that invests in healthcare, pharmaceutical, and biotech startups. It is searching for leading players that fulfill the rapidly growing needs in a nascent innovation-driven ecosystem in China.

3H Health Investment is a dedicated healthcare private equity fund focusing on China. The company invests in pharmaceutical, healthcare services, medical devices, healthcare consumption, and other fields.